There’s no solid clinical data on a defined withdrawal syndrome from BPC-157, mostly since there’s no reliable clinical knowledge on A great deal of anything with this peptide in humans. That absence of evidence isn’t the same as an absence of danger. If BPC-157 does meaningfully interact with dopam